RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical Outcome.

[1]  M. Oki,et al.  Phase 3 Clinical Trial for the Combination of Erlotinib plus Ramucirumab Compared with Osimertinib in Previously Untreated Advanced or Recurrent Non–Small Cell Lung Cancer Positive for the L858R Mutation of EGFR: REVOL858R (WJOG14420L) , 2021, Clinical Lung Cancer.

[2]  G. Shapiro,et al.  516MO Phase I/II study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with solid tumor malignancies , 2021, Annals of Oncology.

[3]  C. Gridelli,et al.  1207O Bevacizumab + erlotinib vs erlotinib alone as first-line treatment of pts with EGFR mutated advanced non squamous NSCLC: Final analysis of the multicenter, randomized, phase III BEVERLY trial , 2021, Annals of Oncology.

[4]  Ying Cheng,et al.  Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study. , 2021, Cancer cell.

[5]  R. Stahel,et al.  VP3-2021: A randomized phase II study of second-line osimertinib (Osi) and bevacizumab (Bev) versus Osi in advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and T790M mutations (mt): Results from the ETOP BOOSTER trial , 2021, Annals of Oncology.

[6]  G. Blandino.  Drugging the Master Regulator TP53 in Cancer: Mission Possible? , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  N. Hanna,et al.  P76.62 RAMOSE: An Open-Label Randomized Phase II Study of Osimertinib with or without Ramucirumab in TKI-Naïve EGFR-Mutant Metastatic NSCLC , 2021 .

[8]  Jiqiang Yao,et al.  Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  K. Kiura,et al.  VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene‐driven non‐small‐cell lung cancers , 2021, Cancer science.

[10]  Cheng-Bo Han,et al.  Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review , 2020, Frontiers in Oncology.

[11]  Yi-long Wu,et al.  Predictive and Prognostic Potential of TP53 in Patients With Advanced Non-Small-Cell Lung Cancer Treated With EGFR-TKI: Analysis of a Phase III Randomized Clinical Trial (CTONG 0901). , 2020, Clinical lung cancer.

[12]  X. Le,et al.  Dual EGFR/VEGF pathway inhibition: a promising strategy for patients with EGFR-mutant NSCLC. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[13]  L. Spaggiari,et al.  Understanding EGFR heterogeneity in lung cancer , 2020, ESMO Open.

[14]  M. Duffy,et al.  Targeting p53 for the treatment of cancer. , 2020, Seminars in cancer biology.

[15]  M. Fassan,et al.  TP53 Mutation Analysis in Gastric Cancer and Clinical Outcomes of Patients with Metastatic Disease Treated with Ramucirumab/Paclitaxel or Standard Chemotherapy , 2020, Cancers.

[16]  K. Nishio,et al.  RELAY+: Exploratory study of ramucirumab plus gefitinib in untreated patients (pts) with epidermal growth factor receptor (EGFR)-mutated metastatic non-small cell lung cancer (NSCLC). , 2020 .

[17]  L. Landi,et al.  Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs , 2020, Journal of clinical medicine.

[18]  H. Hou,et al.  Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis , 2019, BMC Cancer.

[19]  J. Shih,et al.  Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2019, The Lancet. Oncology.

[20]  Yufen Zhao,et al.  Association between TP53 mutations and efficacy of Osimertinib for brain metastasis from EGFR-mutant lung cancer , 2019, Annals of Oncology.

[21]  D. Pe’er,et al.  Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[22]  E. Giovannetti,et al.  Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer , 2019, British Journal of Cancer.

[23]  R. Kurzrock,et al.  Mutated TP53 is a marker of increased VEGF expression: analysis of 7,525 pan-cancer tissues , 2019, Cancer biology & therapy.

[24]  R. Franco,et al.  Molecular heterogeneity in lung cancer: from mechanisms of origin to clinical implications , 2019, International journal of medical sciences.

[25]  Chuantao Zhang,et al.  Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC , 2019, Cancer management and research.

[26]  T. Yamanaka,et al.  A multicenter, open label, randomized phase II study of osimertinib plus ramucirumab versus osimertinib alone as initial chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer: TORG1833. , 2019, Journal of Clinical Oncology.

[27]  T. Yamanaka,et al.  The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV , 2019, International Journal of Clinical Oncology.

[28]  A. Gemma,et al.  Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. , 2019, The Lancet. Oncology.

[29]  Matthew P. Goetz,et al.  NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY , 2019 .

[30]  C. Langer,et al.  Influence of TP53 Mutation on Survival in Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer. , 2018, JCO precision oncology.

[31]  Ying Cheng,et al.  Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[32]  B. Han,et al.  First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  S. Kobayashi,et al.  Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes. , 2017, Lung cancer.

[34]  Matteo Canale,et al.  Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors , 2016, Clinical Cancer Research.

[35]  R. Yelensky,et al.  TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics , 2016, Molecular Cancer Therapeutics.

[36]  T. Yen,et al.  Missense mutations in the TP53 DNA-binding domain predict outcomes in patients with advanced oral cavity squamous cell carcinoma , 2016, Oncotarget.

[37]  D. Liebner,et al.  TP53 mutational status is predictive of pazopanib response in advanced sarcomas. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  S Senan,et al.  Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[39]  L. Sequist,et al.  Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. , 2015, The Lancet. Oncology.

[40]  Pierre Validire,et al.  VEGF-A Expression Correlates with TP53 Mutations in Non-Small Cell Lung Cancer: Implications for Antiangiogenesis Therapy. , 2015, Cancer research.

[41]  R. Rosell,et al.  Nondisruptive p53 Mutations Are Associated with Shorter Survival in Patients with Advanced Non–Small Cell Lung Cancer , 2014, Clinical Cancer Research.

[42]  G. Bhanot,et al.  Potential tumorigenic programs associated with TP53 mutation status reveal role of VEGF pathway , 2012, British Journal of Cancer.

[43]  A. Mes-Masson,et al.  p53 inhibits angiogenesis by inducing the production of Arresten. , 2012, Cancer research.

[44]  Akira Mogi,et al.  TP53 Mutations in Nonsmall Cell Lung Cancer , 2011, Journal of biomedicine & biotechnology.

[45]  N. Ridgway,et al.  Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update. , 2011, Journal of thoracic disease.

[46]  H. Greulich,et al.  The genomics of lung adenocarcinoma: opportunities for targeted therapies. , 2010, Genes & cancer.

[47]  Y. Yatabe,et al.  EGFR T790M mutation: a double role in lung cancer cell survival? , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[48]  J. Manola,et al.  TP53 mutations and survival in squamous-cell carcinoma of the head and neck. , 2007, The New England journal of medicine.

[49]  Michael R. Green,et al.  Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome , 2007, Journal of Molecular Medicine.

[50]  J. Bergh,et al.  The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.